Filgrastim (Neupogen®) is a recombinant, non-pegylated human granulocyte colony stimulating factor (G-CSF) analogue. It binds to the G-CSF receptor and stimulates the production of neutrophils in the bone marrow. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Filgrastim is used in patients with acute myeloid leukemia receiving induction or consolidation chemotherapy. It is also used in cancer patients receiving bone marrow transplant. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. BioVision’s BioSimTM anti-Filgrastim ELISA kit is designed to detect antibody against Filgrastim with high specificity and sensitivity in biological matrices.
产品特点
Easy, convenient, sensitive and time-saving method to measure the level of antibody against Filgrastim in human serum and plasma.
Detection Range: 3.1 - 50 ng/ml
Sensitivity: 3 ng/ml
Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100)
Cross Reactivity: Filgrastim (Neupogen®) infusion camouflages/masks the presence of antibody to Filgrastim (ATT) in serum/plasma samples. Therefore, blood sampling time is critical for detection of ATT. It is convenient to obtain blood sample just before the infusion of Filgrastim or at least 2 weeks after the infusion of Filgrastim.
Recovery rate: 85 – 115% with normal human serum samples with known concentrations
